WAFERLOGIX Trademark

Trademark Overview

On Wednesday, July 19, 2023, a trademark application was filed for WAFERLOGIX with the United States Patent and Trademark Office. The USPTO has given the WAFERLOGIX trademark a serial number of 79377279. The federal status of this trademark filing is REGISTERED as of Tuesday, February 11, 2025. This trademark is owned by iX Biopharma Ltd. The WAFERLOGIX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and nutraceutical preparations for therapeutic or medical purposes in the form of dissolvable wafers that facilitate the delivery of a wide variety of pharmaceutical and nutraceutical actives for the treatment of viral diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, gastrointestinal diseases, endocrine and metabolic diseases, autoimmune diseases, cancer, genetic disorders, musculoskeletal diseases, renal (kidney) diseases, skin diseases, haematological diseases, psychiatric disorders, immunodeficiency disorders, eye and ear disorders, reproductive and gynaecological diseases, oral and dental diseases, allergic diseases, rare and orphan diseases, nutritional diseases, rheumatic diseases, vascular diseases, liver diseases, urinary tract diseases, and sleep disorders
waferlogix

General Information

Serial Number79377279
Word MarkWAFERLOGIX
Filing DateWednesday, July 19, 2023
Status700 - REGISTERED
Status DateTuesday, February 11, 2025
Registration Number7682981
Registration DateTuesday, February 11, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2024

Trademark Statements

Goods and ServicesPharmaceutical and nutraceutical preparations for therapeutic or medical purposes in the form of dissolvable wafers that facilitate the delivery of a wide variety of pharmaceutical and nutraceutical actives for the treatment of viral diseases, infectious diseases, cardiovascular diseases, respiratory diseases, neurological diseases, gastrointestinal diseases, endocrine and metabolic diseases, autoimmune diseases, cancer, genetic disorders, musculoskeletal diseases, renal (kidney) diseases, skin diseases, haematological diseases, psychiatric disorders, immunodeficiency disorders, eye and ear disorders, reproductive and gynaecological diseases, oral and dental diseases, allergic diseases, rare and orphan diseases, nutritional diseases, rheumatic diseases, vascular diseases, liver diseases, urinary tract diseases, and sleep disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 25, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameiX Biopharma Ltd
Party Type30 - Original Registrant
Legal Entity Type24 - NOT AVAILABLE
AddressSG
Party NameiX Biopharma Ltd
Party Type20 - Owner at Publication
Legal Entity Type24 - NOT AVAILABLE
AddressSG
Party NameiX Biopharma Ltd
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressSG

Trademark Events

Event DateEvent Description
Thursday, August 24, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 25, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 25, 2024ASSIGNED TO EXAMINER
Monday, March 25, 2024NON-FINAL ACTION WRITTEN
Friday, April 12, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, April 25, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 29, 2023APPLICATION FILING RECEIPT MAILED
Tuesday, March 26, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, April 12, 2024REFUSAL PROCESSED BY MPU
Thursday, April 25, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 25, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 8, 2024REFUSAL PROCESSED BY IB
Tuesday, June 11, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, June 11, 2024FINAL REFUSAL WRITTEN
Tuesday, June 11, 2024FINAL REFUSAL E-MAILED
Tuesday, July 30, 2024ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Tuesday, July 30, 2024NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Thursday, October 17, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 17, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 3, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 3, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, July 3, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 30, 2024ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Thursday, October 17, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, December 2, 2024ASSIGNED TO EXAMINER
Monday, December 2, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, January 22, 2025NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, January 22, 2025NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Saturday, February 8, 2025NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, February 11, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sunday, May 11, 2025FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, August 27, 2025FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, August 27, 2025FINAL DISPOSITION PROCESSED
Tuesday, February 11, 2025REGISTERED-PRINCIPAL REGISTER
Friday, September 12, 2025FINAL DECISION TRANSACTION PROCESSED BY IB

Related Keywords

waferlogix diseases disorders pharmaceutical nutraceutical psychiatric immunodeficiency haematological reproductive kidney musculoskeletal